Cannabigerol (CBG) is one of more than 150 cannabinoids identified in the cannabis plant. However, tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN) are the most studied.
Cannabigerolic acid (CBGa) is derived from an olivetolic acid (a conjugated acid from an olivetolato). During the growth of the cannabis plant, the CBGa or CBG in acid form is converted into THCa, CBDa or CBCa, under the action of certain enzymes that metabolize and decompose the CBGa.
Later decarboxylation gives fruit to the phytocannabinoids THC, CBD and CBC, among others. However, the direct elimination of a carboxyl group in the CBGa forms the CBG in the plant, approximately 1%.
How does the CBG work?
An article published in the British Jounal of Pharmacology suggests that it acts as a potent agonist (activator) of the alpha-2 adrenergic receptor, and antagonist (blocker) of the 5-HT1A receptor.
In addition, it interacts with the CB1 receptor as a competitive antagonist (blocker that competes for activator binding sites), mainly affecting the central nervous system. Also, it has significant affinity for CB2 receptors. However, the researchers have not yet concluded whether their function in these receptors is agonist or antagonist.
Therapeutic effects of CBG
A study published in 2009 on glaucoma in animals showed that both THC and CBG could reduce intraocular pressure. It should also be borne in mind that cannabigerol is a non-psychoactive substance.
Another scientific article argues that CBG may decrease the progression of colorectal cancer, by selectively inhibiting the growth of tumor cells, blocking transient potential channels (TRPs), which are involved in the growth of tumor cells.
Old publications support its analgesic, antibacterial, anti-inflammatory, antidepressant and antihypertensive effect. Another interesting aspect of cannabigerol is that at high doses it proved to have the property of being cytotoxic in carcinoma of epithelial cells and breast cancer, as well as being a good inhibitor in the proliferation of keratocinocytes, potentially therapeutic in psoriasis. At the experimental level, the CBG could positively help the treatment of intestinal inflammatory diseases.
Finally, a study in 2015 with mice explains that CBG has a promising neuroprotective effect for the treatment of Huntington's disease. Other diseases such as Parkinson's or multiple sclerosis They could also benefit from this property. In spite of the above, it is necessary to carry out studies in humans to clarify the side effects, the necessary doses, or even the result with a combination of phytocannabinoids.
What future does the CBG have?
Being a non-psychoactive substance opens the way for medical research. Unfortunately, due to its low concentration in the cannabis plant, the CBG is difficult to produce in large quantities. This aspect makes it less attractive than CBD, whose concentration is very high.
Even so, better cultivation methods are being studied to increase the amount of cannabigerol in the plant, since it has been discovered that harvesting the cannabis plant after six weeks of flowering, instead of eight weeks, allows a better concentration of cannabis to be obtained. CBG
Did you like this post? Make an assessment. This post has been made based on existing research until the date of publication of the article. Due to the increase of studies around medical cannabis, the information exposed may vary over time and we will inform in subsequent writings.
 CASCIO MG, et alt. Evidence that the plant annabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacology 2010; 159: 129-141.
 BRENDA K. COLASANTI. A Comparison of the Ocular and Central Effects of Δ9-Tetrahydrocannabinol and Cannabigerol. Journal of Ocular Pharmacology and Therapeutics. Jan 1990. Published in Volume: 6 Issue 4: March 18, 2009
 BORRELLI, FRANCESCA et alt. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Volume 35, Issue 12, 1 December 2014, Pages 2787-2797
 BORRELLI, F. et alt. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem. Pharmacol. 2013, 85, 1306-1316
 Valdeolivas S, et alt. Neuroprotective properties of cannabigerol in huntington's disease: Studies in r6 / 2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics. 2015; 12: 185-199. doi: 10.1007 / s13311-014-0304-z
 Garcia C. et alt. Benefits of vce-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental parkinson's disease: Possible involvement of different binding sites at the recipient ppargamma. Journal of Neuroinflammation. 2018; 15: 19. doi: 10.1186 / s12974-018-1060-5
 Farm A.G., et al. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. J. Neuroimmune Pharmacol. 2012; 7: 1002-1016. doi: 10.1007 / s11481-012-9399-3
Here is what you want to know before visiting your regional medical dispensary:You may require a physician’s recommendation, medical cannabis certification, and/or whatever appropriate documentation is needed by your condition. Typically, you need to be 18 or older to be eligible for a medical consent, but exceptions may be made in some states for minors with particularly debilitating conditions. You will usually enroll with a medicinal dispensary. This is to maintain your medical cannabis recommendation or certification on file for legal and regulatory purposes. There will be a waiting space. This is to control the flow of patients and product, but a simple dividing wall gives patients solitude and direct one-on-one contact with a budtender to candidly discuss medical issues. Many times, but not necessarily, your purchases will be tracked by medical dispensaries. This procedure can assist budtenders and patients track effective medication as well as have a living record of manufacturers and goods for future reference and follow up. Medicinal dispensaries usually permit you to smell and analyze the buds prior to buy. This might differ from state-to-state.
Yes, municipal approval is necessary before the AGLC will issue a retail cannabis license. Applicants should get in touch with their intended municipality to learn requirements regarding municipal retail cannabis laws, zoning requirements, land-use restrictions, and location requirements regarding how near a retail shop is to a provincial medical care facility, school, or parcel of property designated as a school book.
Keep non-medical cannabis legal Adults that are 19 decades or older are able to:Possess up to 30 g of authorized dried cannabis or the equivalent in their person. Share up to 30 gram of legal cannabis with other adults in Canada. Purchase cannabis products from a Yukon Liquor Corporation licensed retailer. Grow up to four crops per household. It is illegal to provide non-medical cannabis to anyone under the age of 19 and for anybody below the age of 19 to have any quantity of anti inflammatory cannabis in Yukon.It is illegal and dangerous to drive while under the influence of cannabis or other intoxicants.